首页 > 最新文献

Clinical and Translational Oncology最新文献

英文 中文
lncSNHG16 promotes hepatocellular carcinoma development by inhibiting autophagy lncSNHG16通过抑制自噬促进肝细胞癌的发展
Pub Date : 2024-09-19 DOI: 10.1007/s12094-024-03730-y
Zhu-Jian Deng, Hao-Tian Liu, Bao-Hong Yuan, Li-Xin Pan, Yu-Xian Teng, Jia-Yong Su, Cheng-Piao Luo, Ping-Ping Guo, Jian-Hong Zhong

Objective

To investigate the expression of long non-coding RNA lncSNHG16 in hepatocellular carcinoma (HCC), associations between its expression and patient survival, and its potential role in regulating autophagy in the disease.

Methods

Expression of lncSNHG16 was measured using quantitative real-time PCR in HCC cells in culture and HCC tissues from patients. Effects of lncSNHG16 overexpression were examined in HCC cultures using assays of cell proliferation, wound healing, and migration or invasion in Transwell dishes. Effects of lncSNHG16 overexpression were also examined in subcutaneous tumor in mice. Relationships of lncSNHG16 expression to autophagy and apoptosis in HCC cultures were explored using western blotting and flow cytometry.

Results

Higher lncSNHG16 expression in HCC tissues was associated with significantly worse overall and recurrence-free survival of patients. Overexpressing lncSNHG16 in HCC cell culture promoted cell proliferation, migration, and invasion while suppressing apoptosis. lncSNHG16 was associated with upregulation of STAT3 as well as inhibition of autophagy and associated apoptosis. Overexpressing lncSNHG16 accelerated tumor growth and weight in mice.

Conclusion

The non-coding RNA lncSNHG16 suppresses autophagy and associated apoptosis in HCC, making it a potential therapeutic target.

目的研究长非编码RNA lncSNHG16在肝细胞癌(HCC)中的表达、其表达与患者存活率之间的关系,以及其在该疾病中调节自噬的潜在作用。方法采用定量实时PCR技术测定lncSNHG16在培养的HCC细胞和患者HCC组织中的表达。在HCC培养物中使用细胞增殖、伤口愈合和Transwell培养皿中的迁移或侵袭检测lncSNHG16过表达的影响。在小鼠皮下肿瘤中也检测了lncSNHG16过表达的影响。结果HCC组织中较高的lncSNHG16表达与患者较差的总生存期和无复发生存期有关。在HCC细胞培养中过表达lncSNHG16可促进细胞增殖、迁移和侵袭,同时抑制细胞凋亡。结论 非编码 RNA lncSNHG16 可抑制 HCC 中的自噬和相关凋亡,使其成为一个潜在的治疗靶点。
{"title":"lncSNHG16 promotes hepatocellular carcinoma development by inhibiting autophagy","authors":"Zhu-Jian Deng, Hao-Tian Liu, Bao-Hong Yuan, Li-Xin Pan, Yu-Xian Teng, Jia-Yong Su, Cheng-Piao Luo, Ping-Ping Guo, Jian-Hong Zhong","doi":"10.1007/s12094-024-03730-y","DOIUrl":"https://doi.org/10.1007/s12094-024-03730-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>To investigate the expression of long non-coding RNA lncSNHG16 in hepatocellular carcinoma (HCC), associations between its expression and patient survival, and its potential role in regulating autophagy in the disease.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Expression of lncSNHG16 was measured using quantitative real-time PCR in HCC cells in culture and HCC tissues from patients. Effects of lncSNHG16 overexpression were examined in HCC cultures using assays of cell proliferation, wound healing, and migration or invasion in Transwell dishes. Effects of lncSNHG16 overexpression were also examined in subcutaneous tumor in mice. Relationships of lncSNHG16 expression to autophagy and apoptosis in HCC cultures were explored using western blotting and flow cytometry.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Higher lncSNHG16 expression in HCC tissues was associated with significantly worse overall and recurrence-free survival of patients. Overexpressing lncSNHG16 in HCC cell culture promoted cell proliferation, migration, and invasion while suppressing apoptosis. lncSNHG16 was associated with upregulation of STAT3 as well as inhibition of autophagy and associated apoptosis. Overexpressing lncSNHG16 accelerated tumor growth and weight in mice.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The non-coding RNA lncSNHG16 suppresses autophagy and associated apoptosis in HCC, making it a potential therapeutic target.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of major postoperative complications in cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy 伴有或不伴有腹腔内热化疗的细胞剥脱手术术后主要并发症的预测因素
Pub Date : 2024-09-18 DOI: 10.1007/s12094-024-03725-9
Ana Tejedor, Marina Vendrell, Lana Bijelic, Jaume Tur, Marina Bosch, Graciela Martínez-Pallí

Purpose

Cytoreductive Surgery (CRS) ± Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is associated with a high incidence of postoperative morbidity. Our aim was to identify independent, potentially actionable perioperative predictors of major complications.

Methods

We reviewed patients who underwent CRS ± HIPEC from June 2020 to January 2022 at a high-volume center. Postoperative complications were categorized using the Comprehensive Complication Index, with the upper quartile defining major complications. Multivariate logistic analysis identified predictive and protective factors.

Results

Of 168 patients, 119 (70.8%) underwent HIPEC. Mean Comprehensive Complication Index was 12.6 (12.7) and upper quartile cut-off was 22.6. Medical complications were more frequent but less severe than surgical (63% vs 18%). Forty-six patients (27.4%) comprised the “major complications” group (mean CCI 30.1 vs 6.3). Multivariate logistic regression showed that heart disease (RR 1.9; 95% CI: 1.1 to 3.3), number of anastomoses (RR 2.4; 95% CI:1.3 to 4.6) and first 24-h fluid balance (RR 1.1; 95% CI: 1.1 to 1.2), were independently associated as risk factors for major complications, while opioid-free anesthesia (RR 0.6; 95% CI: 0.3 to 0.9) and high preoperative hemoglobin (RR 0.9; CI 95%: 0.9 to 0.9) were independent-protective factors.

Conclusion

Preoperative heart diseases, number of anastomoses and first 24 h-fluid balance are independent risk factors for major postoperative complications, while high preoperative hemoglobin and opioid-free anesthesia are protective. Correction of anemia prior to surgery, avoiding positive fluid balance and incorporation of opioid-free anesthesia strategy are potential actionable measures to reduce postoperative morbidity.

目的胰腺切除手术(CRS)±腹腔内热化疗(HIPEC)与术后高发病率相关。我们的目的是确定主要并发症的独立、潜在的围手术期预测因素。方法我们回顾了 2020 年 6 月至 2022 年 1 月期间在一家高流量中心接受 CRS±HIPEC 的患者。术后并发症采用综合并发症指数进行分类,上四分位数定义为主要并发症。结果 在168名患者中,119人(70.8%)接受了HIPEC治疗。综合并发症指数平均值为 12.6 (12.7),上四分位数临界值为 22.6。内科并发症的发生率较高,但严重程度低于外科并发症(63% 对 18%)。46名患者(27.4%)属于 "主要并发症 "组(平均CCI 30.1 vs 6.3)。多变量逻辑回归显示,心脏病(RR 1.9;95% CI:1.1 至 3.3)、吻合口数量(RR 2.4;95% CI:1.3 至 4.6)和首次 24 小时体液平衡(RR 1.1;95% CI:1.1 至 1.2)是主要并发症的独立相关风险因素,而无阿片类药物麻醉(RR 0.6;95% CI:0.3 至 0.9)和术前高血红蛋白(RR 0.1;95% CI:0.1 至 0.2)是主要并发症的独立相关风险因素。结论术前心脏病、吻合口数量和前 24 小时体液平衡是术后主要并发症的独立危险因素,而术前高血红蛋白和无阿片类麻醉则具有保护作用。术前纠正贫血、避免体液正平衡和采用无阿片类药物麻醉策略是降低术后发病率的潜在可行措施。
{"title":"Predictors of major postoperative complications in cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy","authors":"Ana Tejedor, Marina Vendrell, Lana Bijelic, Jaume Tur, Marina Bosch, Graciela Martínez-Pallí","doi":"10.1007/s12094-024-03725-9","DOIUrl":"https://doi.org/10.1007/s12094-024-03725-9","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Cytoreductive Surgery (CRS) ± Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is associated with a high incidence of postoperative morbidity. Our aim was to identify independent, potentially actionable perioperative predictors of major complications.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We reviewed patients who underwent CRS ± HIPEC from June 2020 to January 2022 at a high-volume center. Postoperative complications were categorized using the Comprehensive Complication Index, with the upper quartile defining major complications. Multivariate logistic analysis identified predictive and protective factors.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Of 168 patients, 119 (70.8%) underwent HIPEC. Mean Comprehensive Complication Index was 12.6 (12.7) and upper quartile cut-off was 22.6. Medical complications were more frequent but less severe than surgical (63% vs 18%). Forty-six patients (27.4%) comprised the “major complications” group (mean CCI 30.1 vs 6.3). Multivariate logistic regression showed that heart disease (RR 1.9; 95% CI: 1.1 to 3.3), number of anastomoses (RR 2.4; 95% CI:1.3 to 4.6) and first 24-h fluid balance (RR 1.1; 95% CI: 1.1 to 1.2), were independently associated as risk factors for major complications, while opioid-free anesthesia (RR 0.6; 95% CI: 0.3 to 0.9) and high preoperative hemoglobin (RR 0.9; CI 95%: 0.9 to 0.9) were independent-protective factors.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Preoperative heart diseases, number of anastomoses and first 24 h-fluid balance are independent risk factors for major postoperative complications, while high preoperative hemoglobin and opioid-free anesthesia are protective. Correction of anemia prior to surgery, avoiding positive fluid balance and incorporation of opioid-free anesthesia strategy are potential actionable measures to reduce postoperative morbidity.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"63 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes 坎瑞珠单抗联合化疗治疗晚期胆道恶性肿瘤的疗效和安全性以及外周血淋巴细胞亚群与临床结果之间的关系
Pub Date : 2024-09-18 DOI: 10.1007/s12094-024-03707-x
Jian Zhao, Hongxing Guo, Chenxuan Wu, Hongsheng Guo

Background

Biliary tract cancer (BTC) is a highly heterogeneous aggressive tumor, and advanced patients have poor prognosis. This work aimed to evaluate the efficacy and safety of camrelizumab combined with chemotherapy in treating advanced BTC, and to explore predictive biomarkers for distinguishing effective population.

Methods

183 advanced BTC patients admitted from September 2018 to September 2021 were retrospectively selected. 93 patients were treated with camrelizumab combined with chemotherapy (C+C group) and 90 patients were treated with chemotherapy alone (C group). Objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and median overall survival (mOS) were analyzed between two groups. Peripheral blood lymphocyte subsets were assessed by flow cytometry pre- and post-treatment.

Results

The mPFS (6.9 months) and mOS (12.1 months) in the C+C group were significantly longer than those in the C group, which were 5.2 months and 9.8 months respectively (HR 0.46, 95% CI 0.38–0.54, p=0.017; HR 0.39, 95% CI 0.32–0.47, p=0.033). The percentage of Total T, CD4+T, natural killer (NK) cells, lymphocyte, and CD4+/CD8+ cell ratios were significantly increased in effective patients after C+C treatment, but didn’t increase in progressive disease (PD) patients. Higher percentage of Total T, CD4+T, and higher CD4+/CD8+ cell ratios post-treatment were associated with longer OS.

Conclusions

Camrelizumab combining chemotherapy significantly prolonged the mPFS and mOS of advanced BTC patients. Immunotherapy may improve the immune status of advanced patients, and immunotherapy efficacy might be predicted based on the peripheral blood lymphocyte subsets.

背景胆道癌(BTC)是一种高度异质性的侵袭性肿瘤,晚期患者预后较差。本研究旨在评估坎瑞珠单抗联合化疗治疗晚期BTC的疗效和安全性,并探索区分有效人群的预测性生物标志物。方法回顾性选取2018年9月至2021年9月收治的183例晚期BTC患者。93例患者接受康瑞珠单抗联合化疗治疗(C+C组),90例患者接受单纯化疗治疗(C组)。分析了两组患者的客观反应率(ORR)、疾病控制率(DCR)、中位无进展生存期(mPFS)和中位总生存期(mOS)。结果 C+C组的mPFS(6.9个月)和mOS(12.1个月)明显长于C组,分别为5.2个月和9.8个月(HR 0.46,95% CI 0.38-0.54,p=0.017;HR 0.39,95% CI 0.32-0.47,p=0.033)。C+C治疗后,有效患者的总T细胞百分比、CD4+T细胞百分比、自然杀伤(NK)细胞百分比、淋巴细胞百分比和CD4+/CD8+细胞比值显著增加,但进展期疾病(PD)患者的这一指标没有增加。结论康利珠单抗联合化疗可明显延长晚期BTC患者的mPFS和mOS。免疫治疗可改善晚期患者的免疫状态,根据外周血淋巴细胞亚群可预测免疫治疗的疗效。
{"title":"Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes","authors":"Jian Zhao, Hongxing Guo, Chenxuan Wu, Hongsheng Guo","doi":"10.1007/s12094-024-03707-x","DOIUrl":"https://doi.org/10.1007/s12094-024-03707-x","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Biliary tract cancer (BTC) is a highly heterogeneous aggressive tumor, and advanced patients have poor prognosis. This work aimed to evaluate the efficacy and safety of camrelizumab combined with chemotherapy in treating advanced BTC, and to explore predictive biomarkers for distinguishing effective population.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>183 advanced BTC patients admitted from September 2018 to September 2021 were retrospectively selected. 93 patients were treated with camrelizumab combined with chemotherapy (C+C group) and 90 patients were treated with chemotherapy alone (C group). Objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and median overall survival (mOS) were analyzed between two groups. Peripheral blood lymphocyte subsets were assessed by flow cytometry pre- and post-treatment.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The mPFS (6.9 months) and mOS (12.1 months) in the C+C group were significantly longer than those in the C group, which were 5.2 months and 9.8 months respectively (HR 0.46, 95% CI 0.38–0.54, <i>p</i>=0.017; HR 0.39, 95% CI 0.32–0.47, <i>p</i>=0.033). The percentage of Total T, CD4+T, natural killer (NK) cells, lymphocyte, and CD4+/CD8+ cell ratios were significantly increased in effective patients after C+C treatment, but didn’t increase in progressive disease (PD) patients. Higher percentage of Total T, CD4+T, and higher CD4+/CD8+ cell ratios post-treatment were associated with longer OS.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Camrelizumab combining chemotherapy significantly prolonged the mPFS and mOS of advanced BTC patients. Immunotherapy may improve the immune status of advanced patients, and immunotherapy efficacy might be predicted based on the peripheral blood lymphocyte subsets.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety profile of trastuzumab originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials 曲妥珠单抗原研药与生物仿制药的安全性对比:随机临床试验的系统回顾和荟萃分析
Pub Date : 2024-09-18 DOI: 10.1007/s12094-024-03642-x
Andrea Oliva, Cristina Scavone, Consiglia Riccardi, Francesca Futura Bernardi, Francesco Salvo, Annamaria Mascolo

Purpose

In the last decade trastuzumab biosimilars became more and more frequent. Among their uses, from several years, they have been available in Europe for the treatment of HER2-positive metastatic breast cancer, as an alternative to Herceptin®.

Methods/Patients

This meta-analysis aimed to analyze the available literature with particular focus on phase 3 randomized clinical trials (RCTs) comparing adverse events between trastuzumab biosimilar and originator. A systematic review was conducted in Pubmed and Scopus to include all phase 3 RCTs related to trastuzumab in patients with HER2-positive breast cancer and published up to July 31, 2023. Of the 508 records identified, 14 articles were meta-analyzed for safety information, including serious treatment emergent adverse events, death-related adverse events, neutropenia, leukopenia, infections, increased ALT, increased AST, anti-drug antibody, and neutralizing antibody.

Results

Included patients had an early breast cancer (N=2,877) or a metastatic breast cancer (N=2,603). No significant difference in death-related adverse events was found for trastuzumab biosimilar and originator when evaluated for an early breast cancer in the neoadjuvant phase (Risk Ratio [RR], 1.30; 95% confidence interval [CI], 0.47-3.59; I2 = 0%; p = 0.57) and overall (RR, 0.43; 95%CI, 0.11-1.66; I2 = 20%; p = 0.26), and for metastatic breast cancer (RR, 0.61; 95%CI, 0.30-1.26; I2 = 0%; p = 0.85).

Conclusions

No difference was also observed for all other safety outcomes as in accordance with clinical studies necessary for the registration and approval of a biosimilar at a European level.

目的 在过去十年中,曲妥珠单抗生物仿制药的使用越来越频繁。方法/患者这项荟萃分析旨在分析现有文献,尤其侧重于比较曲妥珠单抗生物仿制药和原研药之间不良事件的 3 期随机临床试验 (RCT)。我们在Pubmed和Scopus上进行了系统性回顾,纳入了截至2023年7月31日发表的所有与曲妥珠单抗治疗HER2阳性乳腺癌患者相关的3期随机临床试验。在确定的508条记录中,对14篇文章的安全性信息进行了荟萃分析,包括严重治疗突发不良事件、死亡相关不良事件、中性粒细胞减少症、白细胞减少症、感染、谷丙转氨酶升高、谷草转氨酶升高、抗药抗体和中和抗体。结果纳入的患者有早期乳腺癌(N=2877)或转移性乳腺癌(N=2603)。在对早期乳腺癌进行新辅助治疗阶段(风险比 [RR],1.30;95% 置信区间 [CI],0.47-3.59;I2 = 0%;p = 0.57)和总体治疗阶段(RR,0.43;95%CI,0.11-1.66;I2 = 20%;p = 0.57)的死亡相关不良事件进行评估时,发现曲妥珠单抗生物仿制药与原研药无明显差异。结论根据在欧洲注册和批准生物类似药所需的临床研究,在所有其他安全性结果方面也未观察到差异。
{"title":"Safety profile of trastuzumab originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials","authors":"Andrea Oliva, Cristina Scavone, Consiglia Riccardi, Francesca Futura Bernardi, Francesco Salvo, Annamaria Mascolo","doi":"10.1007/s12094-024-03642-x","DOIUrl":"https://doi.org/10.1007/s12094-024-03642-x","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>In the last decade trastuzumab biosimilars became more and more frequent. Among their uses, from several years, they have been available in Europe for the treatment of HER2-positive metastatic breast cancer, as an alternative to Herceptin®.</p><h3 data-test=\"abstract-sub-heading\">Methods/Patients</h3><p>This meta-analysis aimed to analyze the available literature with particular focus on phase 3 randomized clinical trials (RCTs) comparing adverse events between trastuzumab biosimilar and originator. A systematic review was conducted in Pubmed and Scopus to include all phase 3 RCTs related to trastuzumab in patients with HER2-positive breast cancer and published up to July 31, 2023. Of the 508 records identified, 14 articles were meta-analyzed for safety information, including serious treatment emergent adverse events, death-related adverse events, neutropenia, leukopenia, infections, increased ALT, increased AST, anti-drug antibody, and neutralizing antibody.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Included patients had an early breast cancer (N=2,877) or a metastatic breast cancer (N=2,603). No significant difference in death-related adverse events was found for trastuzumab biosimilar and originator when evaluated for an early breast cancer in the neoadjuvant phase (Risk Ratio [RR], 1.30; 95% confidence interval [CI], 0.47-3.59; I2 = 0%; p = 0.57) and overall (RR, 0.43; 95%CI, 0.11-1.66; I2 = 20%; p = 0.26), and for metastatic breast cancer (RR, 0.61; 95%CI, 0.30-1.26; I2 = 0%; p = 0.85).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>No difference was also observed for all other safety outcomes as in accordance with clinical studies necessary for the registration and approval of a biosimilar at a European level.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging immunologic approaches as cancer anti-angiogenic therapies 作为癌症抗血管生成疗法的新兴免疫学方法
Pub Date : 2024-09-18 DOI: 10.1007/s12094-024-03667-2
Mohammadreza Azimi, Mahdokht Sadat Manavi, Maral Afshinpour, Roya Khorram, Reza Vafadar, Fatemeh Rezaei-Tazangi, Danyal Arabzadeh, Sattar Arabzadeh, Nasim Ebrahimi, Amir Reza Aref

Targeting tumor angiogenesis, the formation of new blood vessels supporting cancer growth and spread, has been an intense focus for therapy development. However, benefits from anti-angiogenic drugs like bevacizumab have been limited by resistance stemming from activation of compensatory pathways. Recent immunotherapy advances have sparked interest in novel immunologic approaches that can induce more durable vascular pruning and overcome limitations of existing angiogenesis inhibitors. This review comprehensively examines these emerging strategies, including modulating tumor-associated macrophages, therapeutic cancer vaccines, engineered nanobodies and T cells, anti-angiogenic cytokines/chemokines, and immunomodulatory drugs like thalidomide analogs. For each approach, the molecular mechanisms, preclinical/clinical data, and potential advantages over conventional drugs are discussed. Innovative therapeutic platforms like nanoparticle delivery systems are explored. Moreover, the importance of combining agents with distinct mechanisms to prevent resistance is evaluated. As tumors hijack angiogenesis for growth, harnessing the immune system’s specificity to disrupt this process represents a promising anti-cancer strategy covered by this review.

针对肿瘤血管生成(支持癌症生长和扩散的新血管的形成)的治疗一直是治疗开发的重点。然而,贝伐珠单抗等抗血管生成药物的疗效因代偿途径的激活而产生的抗药性而受到限制。免疫疗法的最新进展激发了人们对新型免疫方法的兴趣,这种方法可以诱导更持久的血管修剪,并克服现有血管生成抑制剂的局限性。本综述全面探讨了这些新兴策略,包括调节肿瘤相关巨噬细胞、治疗性癌症疫苗、工程纳米抗体和 T 细胞、抗血管生成细胞因子/凝血因子以及沙利度胺类似物等免疫调节药物。本文讨论了每种方法的分子机制、临床前/临床数据以及与传统药物相比的潜在优势。还探讨了纳米颗粒给药系统等创新治疗平台。此外,还评估了结合具有不同机制的药物以防止耐药性的重要性。由于肿瘤会劫持血管生成来促进生长,因此利用免疫系统的特异性来破坏这一过程是本综述所涉及的一种前景广阔的抗癌策略。
{"title":"Emerging immunologic approaches as cancer anti-angiogenic therapies","authors":"Mohammadreza Azimi, Mahdokht Sadat Manavi, Maral Afshinpour, Roya Khorram, Reza Vafadar, Fatemeh Rezaei-Tazangi, Danyal Arabzadeh, Sattar Arabzadeh, Nasim Ebrahimi, Amir Reza Aref","doi":"10.1007/s12094-024-03667-2","DOIUrl":"https://doi.org/10.1007/s12094-024-03667-2","url":null,"abstract":"<p>Targeting tumor angiogenesis, the formation of new blood vessels supporting cancer growth and spread, has been an intense focus for therapy development. However, benefits from anti-angiogenic drugs like bevacizumab have been limited by resistance stemming from activation of compensatory pathways. Recent immunotherapy advances have sparked interest in novel immunologic approaches that can induce more durable vascular pruning and overcome limitations of existing angiogenesis inhibitors. This review comprehensively examines these emerging strategies, including modulating tumor-associated macrophages, therapeutic cancer vaccines, engineered nanobodies and T cells, anti-angiogenic cytokines/chemokines, and immunomodulatory drugs like thalidomide analogs. For each approach, the molecular mechanisms, preclinical/clinical data, and potential advantages over conventional drugs are discussed. Innovative therapeutic platforms like nanoparticle delivery systems are explored. Moreover, the importance of combining agents with distinct mechanisms to prevent resistance is evaluated. As tumors hijack angiogenesis for growth, harnessing the immune system’s specificity to disrupt this process represents a promising anti-cancer strategy covered by this review.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"139 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Construction and clinical significance of prognostic risk markers based on cancer driver genes in lung adenocarcinoma 基于癌症驱动基因的肺腺癌预后风险标记的构建及其临床意义
Pub Date : 2024-09-18 DOI: 10.1007/s12094-024-03703-1
Yazhou Su, Tingting Huo, Yanan Wang, Jingyan Li

Background

Cancer driver genes (CDGs) have been reported as key factors influencing the progression of lung adenocarcinoma (LUAD). However, the role of CDGs in LUAD prognosis has not been fully elucidated.

Methods

LUAD transcriptome data and CDG-related data were obtained from public databases and literature. Differentially expressed CDGs (DE-CDGs) greatly associated with LUAD survival (P < 0.05) were identified to establish a prognostic model. In addition, immune analysis of high-risk (HR) and low-risk (LR) groups was conducted by utilizing the CIBERSORT and single sample gene set enrichment analysis (ssGSEA) algorithms to assess immune differences. Subsequently, mutation analysis was conducted using maftools. Finally, candidate drugs were identified using the CellMiner database.

Results

40 DE-CDGs significantly associated with LUAD survival and 11 DE-CDGs associated with prognosis were identified through screening. Regression analysis revealed that risk score can independently predict LUAD prognosis (P < 0.05). Immune landscape analysis revealed that compared to the HR group, the LR group had higher immune scores and high infiltration of various immune cells such as follicular helper B cells and T cells. Mutation landscape analysis demonstrated that missense mutation was the most common mutation type in both risk groups. Drug prediction analysis revealed strong correlations of fulvestrant, S-63845, sapacitabine, lomustine, BLU-667, SR16157, motesanib, AZD-9496, XK-469, dimethylfasudil, P-529, and imatinib with the model genes, suggesting their potential as candidate drugs targeting the model genes.

Conclusion

This study identified 11 effective biomarkers, DE-CDGs, which can predict LUAD prognosis and explored the biological significance of CDGs in LUAD prognosis, immunotherapy, and treatment.

背景据报道,癌症驱动基因(CDGs)是影响肺腺癌(LUAD)进展的关键因素。方法从公共数据库和文献中获取肺腺癌转录组数据和 CDG 相关数据。方法从公共数据库中获取了LUAD转录组数据和CDG相关数据,确定了与LUAD存活率密切相关的差异表达CDGs(DE-CDGs)(P < 0.05),从而建立了预后模型。此外,还利用 CIBERSORT 和单样本基因组富集分析(ssGSEA)算法对高风险组(HR)和低风险组(LR)进行了免疫分析,以评估免疫差异。随后,使用 maftools 进行了突变分析。结果 通过筛选,发现了40个与LUAD存活率显著相关的DE-CDGs和11个与预后相关的DE-CDGs。回归分析显示,风险评分可独立预测 LUAD 的预后(P < 0.05)。免疫景观分析显示,与HR组相比,LR组的免疫评分更高,各种免疫细胞如滤泡辅助B细胞和T细胞的浸润程度更高。突变情况分析表明,错义突变是两个风险组中最常见的突变类型。药物预测分析表明,氟维司群、S-63845、沙帕他滨、洛莫司汀、BLU-667、SR16157、莫替沙尼、AZD-9496、XK-469、二甲基法舒地尔、P-529和伊马替尼与模型基因有很强的相关性,表明它们有可能成为靶向模型基因的候选药物。结论 本研究发现了11个可预测LUAD预后的有效生物标志物DE-CDGs,并探讨了CDGs在LUAD预后、免疫疗法和治疗中的生物学意义。
{"title":"Construction and clinical significance of prognostic risk markers based on cancer driver genes in lung adenocarcinoma","authors":"Yazhou Su, Tingting Huo, Yanan Wang, Jingyan Li","doi":"10.1007/s12094-024-03703-1","DOIUrl":"https://doi.org/10.1007/s12094-024-03703-1","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Cancer driver genes (CDGs) have been reported as key factors influencing the progression of lung adenocarcinoma (LUAD). However, the role of CDGs in LUAD prognosis has not been fully elucidated.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>LUAD transcriptome data and CDG-related data were obtained from public databases and literature. Differentially expressed CDGs (DE-CDGs) greatly associated with LUAD survival (<i>P</i> &lt; 0.05) were identified to establish a prognostic model. In addition, immune analysis of high-risk (HR) and low-risk (LR) groups was conducted by utilizing the CIBERSORT and single sample gene set enrichment analysis (ssGSEA) algorithms to assess immune differences. Subsequently, mutation analysis was conducted using <i>maftools</i>. Finally, candidate drugs were identified using the CellMiner database.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>40 DE-CDGs significantly associated with LUAD survival and 11 DE-CDGs associated with prognosis were identified through screening. Regression analysis revealed that risk score can independently predict LUAD prognosis (<i>P</i> &lt; 0.05). Immune landscape analysis revealed that compared to the HR group, the LR group had higher immune scores and high infiltration of various immune cells such as follicular helper B cells and T cells. Mutation landscape analysis demonstrated that missense mutation was the most common mutation type in both risk groups. Drug prediction analysis revealed strong correlations of fulvestrant, S-63845, sapacitabine, lomustine, BLU-667, SR16157, motesanib, AZD-9496, XK-469, dimethylfasudil, P-529, and imatinib with the model genes, suggesting their potential as candidate drugs targeting the model genes.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>This study identified 11 effective biomarkers, DE-CDGs, which can predict LUAD prognosis and explored the biological significance of CDGs in LUAD prognosis, immunotherapy, and treatment.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The prevalence of oral mucositis after radiotherapy in patients with Head and Neck Cancer and its associated factors: a meta-analysis 头颈癌患者放疗后口腔黏膜炎的发病率及其相关因素:荟萃分析
Pub Date : 2024-09-14 DOI: 10.1007/s12094-024-03706-y
Enhong Li, Jiang Zeng, Feiruo Hong, Piaopiao Chen, Xuefen Yu

Objectives

Although the discussion about oral mucositis in Head and Neck Cancer (HNC) patients has become a prominent issue, its incidence and influencing factors have not been thoroughly synthesized. This meta-analysis aims to integrate the prevalence and associated factors of radiation-induced oral mucositis among HNC patients.

Methods

This study searched the following electronic databases: PubMed, the Cochrane Database, the Web of Science, EMBASE, CNKI, the Wanfang Database, and the VIP Database. The publication timeframe for the included studies ranged from January 2005 until January 2024. Two investigators used the NOS scale and AHRQ evaluation criteria for quality evaluation. All qualified studies and statistical analyses were conducted using RevMan 5.2 and Stata 17.0.

Results

Thirty eligible studies were included in the analysis. The results show that the prevalence of radiation-induced oral mucositis in HNC patients was 94% [95% CI (89%, 98%)]. Furthermore, the prevalence of severe radiation-induced oral mucositis in HNC patients is 37% [95%CI (29%, 45%)]. Chemotherapy, smoking history, diabetes, oral PH ≤ 7.0, and alcohol consumption are the main risk factors for radioactive oral mucositis. In addition, BMI > 24.0 kg/m2, no use of antibiotics, and no use of oral mucosal protective agents are associated with radioactive oral mucositis.

Conclusions

This meta-analysis underscores a significantly high prevalence of radiation-induced oral mucositis in HNC patients. Establishing healthy lifestyle habits and maintaining a healthy oral environment are pivotal in preventing radiation-induced oral mucositis.

目的尽管有关头颈癌(HNC)患者口腔黏膜炎的讨论已成为一个突出问题,但其发病率和影响因素尚未得到全面综合。本荟萃分析旨在整合 HNC 患者中辐射诱发口腔黏膜炎的发病率和相关因素:本研究检索了以下电子数据库:PubMed、Cochrane 数据库、Web of Science、EMBASE、CNKI、万方数据库和 VIP 数据库。纳入研究的发表时间范围为 2005 年 1 月至 2024 年 1 月。两名研究者使用 NOS 量表和 AHRQ 评估标准进行质量评估。所有合格的研究和统计分析均使用 RevMan 5.2 和 Stata 17.0 进行。结果显示,HNC 患者放射诱发口腔黏膜炎的发生率为 94% [95% CI (89%, 98%)]。此外,HNC 患者中严重辐射诱发口腔黏膜炎的发病率为 37% [95%CI (29%, 45%)]。化疗、吸烟史、糖尿病、口腔 PH ≤ 7.0 和饮酒是放射性口腔黏膜炎的主要危险因素。此外,体重指数(BMI > 24.0 kg/m2)、未使用抗生素和未使用口腔黏膜保护剂也与放射性口腔黏膜炎有关。建立健康的生活习惯和保持健康的口腔环境对预防辐射诱发的口腔黏膜炎至关重要。
{"title":"The prevalence of oral mucositis after radiotherapy in patients with Head and Neck Cancer and its associated factors: a meta-analysis","authors":"Enhong Li, Jiang Zeng, Feiruo Hong, Piaopiao Chen, Xuefen Yu","doi":"10.1007/s12094-024-03706-y","DOIUrl":"https://doi.org/10.1007/s12094-024-03706-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>Although the discussion about oral mucositis in Head and Neck Cancer (HNC) patients has become a prominent issue, its incidence and influencing factors have not been thoroughly synthesized. This meta-analysis aims to integrate the prevalence and associated factors of radiation-induced oral mucositis among HNC patients.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This study searched the following electronic databases: PubMed, the Cochrane Database, the Web of Science, EMBASE, CNKI, the Wanfang Database, and the VIP Database. The publication timeframe for the included studies ranged from January 2005 until January 2024. Two investigators used the NOS scale and AHRQ evaluation criteria for quality evaluation. All qualified studies and statistical analyses were conducted using RevMan 5.2 and Stata 17.0.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Thirty eligible studies were included in the analysis. The results show that the prevalence of radiation-induced oral mucositis in HNC patients was 94% [95% CI (89%, 98%)]. Furthermore, the prevalence of severe radiation-induced oral mucositis in HNC patients is 37% [95%CI (29%, 45%)]. Chemotherapy, smoking history, diabetes, oral PH ≤ 7.0, and alcohol consumption are the main risk factors for radioactive oral mucositis. In addition, BMI &gt; 24.0 kg/m<sup>2</sup>, no use of antibiotics, and no use of oral mucosal protective agents are associated with radioactive oral mucositis.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>This meta-analysis underscores a significantly high prevalence of radiation-induced oral mucositis in HNC patients. Establishing healthy lifestyle habits and maintaining a healthy oral environment are pivotal in preventing radiation-induced oral mucositis.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"122 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing 利用机器学习和自然语言处理建立癌症相关静脉血栓栓塞抗凝患者大出血预测模型
Pub Date : 2024-09-14 DOI: 10.1007/s12094-024-03586-2
Andrés J. Muñoz Martín, Ramón Lecumberri, Juan Carlos Souto, Berta Obispo, Antonio Sanchez, Jorge Aparicio, Cristina Aguayo, David Gutierrez, Andrés García Palomo, Diego Benavent, Miren Taberna, María Carmen Viñuela-Benéitez, Daniel Arumi, Miguel Ángel Hernández-Presa

Purpose

We developed a predictive model to assess the risk of major bleeding (MB) within 6 months of primary venous thromboembolism (VTE) in cancer patients receiving anticoagulant treatment. We also sought to describe the prevalence and incidence of VTE in cancer patients, and to describe clinical characteristics at baseline and bleeding events during follow-up in patients receiving anticoagulants.

Methods

This observational, retrospective, and multicenter study used natural language processing and machine learning (ML), to analyze unstructured clinical data from electronic health records from nine Spanish hospitals between 2014 and 2018. All adult cancer patients with VTE receiving anticoagulants were included. Both clinically- and ML-driven feature selection was performed to identify MB predictors. Logistic regression (LR), decision tree (DT), and random forest (RF) algorithms were used to train predictive models, which were validated in a hold-out dataset and compared to the previously developed CAT-BLEED score.

Results

Of the 2,893,108 cancer patients screened, in-hospital VTE prevalence was 5.8% and the annual incidence ranged from 2.7 to 3.9%. We identified 21,227 patients with active cancer and VTE receiving anticoagulants (53.9% men, median age of 70 years). MB events after VTE diagnosis occurred in 10.9% of patients within the first six months. MB predictors included: hemoglobin, metastasis, age, platelets, leukocytes, and serum creatinine. The LR, DT, and RF models had AUC-ROC (95% confidence interval) values of 0.60 (0.55, 0.65), 0.60 (0.55, 0.65), and 0.61 (0.56, 0.66), respectively. These models outperformed the CAT-BLEED score with values of 0.53 (0.48, 0.59).

Conclusions

Our study shows encouraging results in identifying anticoagulated patients with cancer-associated VTE who are at high risk of MB.

目的我们开发了一种预测模型,用于评估接受抗凝治疗的癌症患者在原发性静脉血栓栓塞(VTE)后 6 个月内发生大出血(MB)的风险。我们还试图描述癌症患者中 VTE 的流行率和发病率,并描述接受抗凝药物治疗的患者基线时的临床特征和随访期间的出血事件。方法这项观察性、回顾性和多中心研究使用自然语言处理和机器学习(ML)分析了 2014 年至 2018 年期间来自九家西班牙医院电子健康记录的非结构化临床数据。研究纳入了所有接受抗凝治疗的VTE成人癌症患者。通过临床和 ML 驱动的特征选择来识别 MB 预测因子。逻辑回归(LR)、决策树(DT)和随机森林(RF)算法被用于训练预测模型,这些模型在保留数据集中进行了验证,并与之前开发的 CAT-BLEED 评分进行了比较。结果在接受筛查的 2893108 名癌症患者中,院内 VTE 患病率为 5.8%,年发病率为 2.7% 至 3.9%。我们发现了 21,227 名患有活动性癌症和 VTE 并正在接受抗凝治疗的患者(53.9% 为男性,中位年龄为 70 岁)。10.9% 的患者在确诊 VTE 后的头六个月内发生了 MB 事件。MB 预测因素包括:血红蛋白、转移、年龄、血小板、白细胞和血清肌酐。LR、DT和RF模型的AUC-ROC(95%置信区间)值分别为0.60(0.55,0.65)、0.60(0.55,0.65)和0.61(0.56,0.66)。结论我们的研究在识别抗凝的癌症相关 VTE 患者中发现了令人鼓舞的结果,这些患者具有 MB 的高风险。
{"title":"Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing","authors":"Andrés J. Muñoz Martín, Ramón Lecumberri, Juan Carlos Souto, Berta Obispo, Antonio Sanchez, Jorge Aparicio, Cristina Aguayo, David Gutierrez, Andrés García Palomo, Diego Benavent, Miren Taberna, María Carmen Viñuela-Benéitez, Daniel Arumi, Miguel Ángel Hernández-Presa","doi":"10.1007/s12094-024-03586-2","DOIUrl":"https://doi.org/10.1007/s12094-024-03586-2","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>We developed a predictive model to assess the risk of major bleeding (MB) within 6 months of primary venous thromboembolism (VTE) in cancer patients receiving anticoagulant treatment. We also sought to describe the prevalence and incidence of VTE in cancer patients, and to describe clinical characteristics at baseline and bleeding events during follow-up in patients receiving anticoagulants.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This observational, retrospective, and multicenter study used natural language processing and machine learning (ML), to analyze unstructured clinical data from electronic health records from nine Spanish hospitals between 2014 and 2018. All adult cancer patients with VTE receiving anticoagulants were included. Both clinically- and ML-driven feature selection was performed to identify MB predictors. Logistic regression (LR), decision tree (DT), and random forest (RF) algorithms were used to train predictive models, which were validated in a hold-out dataset and compared to the previously developed CAT-BLEED score.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Of the 2,893,108 cancer patients screened, in-hospital VTE prevalence was 5.8% and the annual incidence ranged from 2.7 to 3.9%. We identified 21,227 patients with active cancer and VTE receiving anticoagulants (53.9% men, median age of 70 years). MB events after VTE diagnosis occurred in 10.9% of patients within the first six months. MB predictors included: hemoglobin, metastasis, age, platelets, leukocytes, and serum creatinine. The LR, DT, and RF models had AUC-ROC (95% confidence interval) values of 0.60 (0.55, 0.65), 0.60 (0.55, 0.65), and 0.61 (0.56, 0.66), respectively. These models outperformed the CAT-BLEED score with values of 0.53 (0.48, 0.59).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Our study shows encouraging results in identifying anticoagulated patients with cancer-associated VTE who are at high risk of MB.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and impact of metabolic associated fatty liver disease in non-metastatic breast cancer women at initial diagnosis: a cross-sectional study in China 中国非转移性乳腺癌女性初诊时代谢相关性脂肪肝的患病率和影响:一项横断面研究
Pub Date : 2024-09-14 DOI: 10.1007/s12094-024-03665-4
Zhi-yu Jiang, Xin-yu Liang, Lei Hu, Liang Ran, Rui-ling She, Chen-yu Ma, Jun-han Feng, Jing-yu Song, Zhao-xing Li, Xiu-quan Qu, Bai-qing Peng, Kai-nan Wu, Ling-quan Kong

Purpose

The epidemiologic data of metabolic associated fatty liver disease (MAFLD) in breast cancer (BC) patients remains limited. We aimed to investigate the prevalence and clinicopathological characteristics of hepatic steatosis (HS) and MAFLD in Chinese BC women at initial diagnosis.

Methods

3217 non-metastatic primary BC women with MAFLD evaluation indexes at initial diagnosis and 32,170 age-matched (in a 1:10 ratio) contemporaneous health check-up women were enrolled.

Results

The prevalence of HS (21.5% vs. 19.7%, p = 0.013) and MAFLD (20.8% vs. 18.6%, p = 0.002) were significantly higher in BC women than in health check-ups, respectively. Meanwhile, the prevalence of HS/MAFLD among elderly BC women (≥ 60 years) was significantly higher than the health check-ups (38.7%/37.6% vs 31.9%/30.8%), respectively. In BC women with HS/MAFLD, the prevalence of overweight/obesity was up to 85.7%/88.6%, dyslipidemia and elevated blood pressure were 63.2%/63.7% and 59.7%/61.7%, respectively. No statistical significance of the expressions of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER-2) and Ki67 were found between BC women with HS/MAFLD and BC women without HS/MAFLD. After adjustment, BC women with HS showed significantly higher risk of lymph node metastasis than BC women without HS. Subjects with HS/MAFLD had higher risks of overweight/obesity, dyslipidemia, elevated blood pressure, hyperuricemia, and elevated enzymes than those without HS/MAFLD.

Conclusions

Compared with health check-ups, BC patients have higher prevalence of HS/MAFLD. HS/MAFLD coexist with high prevalence of metabolic complications, and the risk of lymph node metastasis was significantly higher in BC women with HS than in BC women without HS.

目的 乳腺癌(BC)患者代谢相关性脂肪肝(MAFLD)的流行病学数据仍然有限。我们旨在调查中国乳腺癌妇女初诊时肝脏脂肪变性(HS)和代谢相关性脂肪肝的患病率和临床病理特征。方法纳入了3217名初诊时有代谢相关性脂肪肝评估指标的非转移性原发性乳腺癌妇女和32170名年龄匹配(1:10比例)的同期健康体检妇女。结果 BC 妇女的 HS 患病率(21.5% 对 19.7%,p = 0.013)和 MAFLD 患病率(20.8% 对 18.6%,p = 0.002)分别显著高于健康体检妇女。同时,老年 BC 妇女(≥ 60 岁)的 HS/MAFLD 患病率明显高于健康体检者(分别为 38.7%/37.6% vs 31.9%/30.8% )。在患有 HS/MAFLD 的 BC 妇女中,超重/肥胖的发生率高达 85.7%/88.6% ,血脂异常和血压升高的发生率分别为 63.2%/63.7% 和 59.7%/61.7% 。雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子2(HER-2)和Ki67的表达在有HS/MAFLD的BC女性和无HS/MAFLD的BC女性之间没有统计学意义。经调整后,患有 HS 的 BC 妇女发生淋巴结转移的风险明显高于未患 HS 的 BC 妇女。 与未患 HS/MAFLD 的受试者相比,患有 HS/MAFLD 的受试者发生超重/肥胖、血脂异常、血压升高、高尿酸血症和酶升高的风险更高。结论与健康体检结果相比,BC 患者的 HS/MAFLD 患病率较高,HS/MAFLD 与代谢并发症的患病率也较高,有 HS 的 BC 妇女发生淋巴结转移的风险明显高于无 HS 的 BC 妇女。
{"title":"Prevalence and impact of metabolic associated fatty liver disease in non-metastatic breast cancer women at initial diagnosis: a cross-sectional study in China","authors":"Zhi-yu Jiang, Xin-yu Liang, Lei Hu, Liang Ran, Rui-ling She, Chen-yu Ma, Jun-han Feng, Jing-yu Song, Zhao-xing Li, Xiu-quan Qu, Bai-qing Peng, Kai-nan Wu, Ling-quan Kong","doi":"10.1007/s12094-024-03665-4","DOIUrl":"https://doi.org/10.1007/s12094-024-03665-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>The epidemiologic data of metabolic associated fatty liver disease (MAFLD) in breast cancer (BC) patients remains limited. We aimed to investigate the prevalence and clinicopathological characteristics of hepatic steatosis (HS) and MAFLD in Chinese BC women at initial diagnosis.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>3217 non-metastatic primary BC women with MAFLD evaluation indexes at initial diagnosis and 32,170 age-matched (in a 1:10 ratio) contemporaneous health check-up women were enrolled.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The prevalence of HS (21.5% vs. 19.7%, <i>p</i> = 0.013) and MAFLD (20.8% vs. 18.6%, <i>p</i> = 0.002) were significantly higher in BC women than in health check-ups, respectively. Meanwhile, the prevalence of HS/MAFLD among elderly BC women (≥ 60 years) was significantly higher than the health check-ups (38.7%/37.6% vs 31.9%/30.8%), respectively. In BC women with HS/MAFLD, the prevalence of overweight/obesity was up to 85.7%/88.6%, dyslipidemia and elevated blood pressure were 63.2%/63.7% and 59.7%/61.7%, respectively. No statistical significance of the expressions of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER-2) and Ki67 were found between BC women with HS/MAFLD and BC women without HS/MAFLD. After adjustment, BC women with HS showed significantly higher risk of lymph node metastasis than BC women without HS. Subjects with HS/MAFLD had higher risks of overweight/obesity, dyslipidemia, elevated blood pressure, hyperuricemia, and elevated enzymes than those without HS/MAFLD.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Compared with health check-ups, BC patients have higher prevalence of HS/MAFLD. HS/MAFLD coexist with high prevalence of metabolic complications, and the risk of lymph node metastasis was significantly higher in BC women with HS than in BC women without HS.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liquid–liquid phase separation-related genes associated with prognosis, tumor microenvironment characteristics, and tumor cell features in bladder cancer 与膀胱癌预后、肿瘤微环境特征和肿瘤细胞特征相关的液相-液相分离基因
Pub Date : 2024-09-13 DOI: 10.1007/s12094-024-03719-7
Xiao-Hui Wu, Xu-Yun Huang, Qi You, Jun-Ming Zhu, Qian-Ren-Shun Qiu, Yun-Zhi Lin, Ning Xu, Yong Wei, Xue-Yi Xue, Ye-Hui Chen, Shao-Hao Chen, Qing-Shui Zheng

Objective

This study aimed to explore the Liquid–liquid phase separation (LLPS)-related genes associated with the prognosis of bladder cancer (BCa) and assess the potential application of LLPS-related prognostic signature for predicting prognosis in BCa patients.

Methods

Clinical information and transcriptome data of BCa patients were extracted from the Cancer Genome Atlas-BLCA (TCGA-BLCA) database and the GSE13507 database. Furthermore, 108 BCa patients who received treatment at our institution were subjected to a retrospective analysis. The least absolute shrinkage and selection operator (LASSO) analysis was performed to develop an LLPS-related prognostic signature for BCa. The CCK8, wound healing and Transwell assays were performed.

Results

Based on 62 differentially expressed LLPS-related genes (DELRGs), three DELRGs were screened by LASSO analysis including kallikrein-related peptidase 5 (KLK5), monoacylglycerol O-acyltransferase 2 (MOGAT2) and S100 calcium-binding protein A7 (S100A7). Based on three DELRGs, a novel LLPS-related prognostic signature was constructed for individualized prognosis assessment. Kaplan–Meier curve analyses showed that LLPS-related prognostic signature was significantly correlated with overall survival (OS) of BCa. ROC analyses demonstrated the LLPS-related prognostic signature performed well in predicting the prognosis of BCa patients in the training group (the area under the curve (AUC) = 0.733), which was externally verified in the validation cohort 1 (AUC = 0.794) and validation cohort 2 (AUC = 0.766). Further experiments demonstrated that inhibiting KLK5 could affect the proliferation, migration, and invasion of BCa cells.

Conclusions

In this study, a novel LLPS-related prognostic signature was successfully developed and validated, demonstrating strong performance in predicting the prognosis of BCa patients.

方法从癌症基因组图谱-BLCA(TCGA-BLCA)数据库和GSE13507数据库中提取BCa患者的临床信息和转录组数据。此外,还对在本院接受治疗的108例BCA患者进行了回顾性分析。通过最小绝对缩小和选择算子(LASSO)分析,建立了与LLPS相关的BCa预后特征。结果基于62个差异表达的LLPS相关基因(DELRGs),通过LASSO分析筛选出3个DELRGs,包括allikrein相关肽酶5(KLK5)、单酰甘油O-酰基转移酶2(MOGAT2)和S100钙结合蛋白A7(S100A7)。根据三个 DELRGs,构建了一个新的 LLPS 相关预后特征,用于个体化预后评估。Kaplan-Meier曲线分析表明,LLPS相关预后特征与BCa的总生存期(OS)显著相关。ROC分析表明,LLPS相关预后特征在预测训练组BCa患者的预后方面表现良好(曲线下面积(AUC)=0.733),这在验证组1(AUC=0.794)和验证组2(AUC=0.766)中得到了外部验证。进一步的实验表明,抑制 KLK5 可影响 BCa 细胞的增殖、迁移和侵袭。
{"title":"Liquid–liquid phase separation-related genes associated with prognosis, tumor microenvironment characteristics, and tumor cell features in bladder cancer","authors":"Xiao-Hui Wu, Xu-Yun Huang, Qi You, Jun-Ming Zhu, Qian-Ren-Shun Qiu, Yun-Zhi Lin, Ning Xu, Yong Wei, Xue-Yi Xue, Ye-Hui Chen, Shao-Hao Chen, Qing-Shui Zheng","doi":"10.1007/s12094-024-03719-7","DOIUrl":"https://doi.org/10.1007/s12094-024-03719-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>This study aimed to explore the Liquid–liquid phase separation (LLPS)-related genes associated with the prognosis of bladder cancer (BCa) and assess the potential application of LLPS-related prognostic signature for predicting prognosis in BCa patients.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Clinical information and transcriptome data of BCa patients were extracted from the Cancer Genome Atlas-BLCA (TCGA-BLCA) database and the GSE13507 database. Furthermore, 108 BCa patients who received treatment at our institution were subjected to a retrospective analysis. The least absolute shrinkage and selection operator (LASSO) analysis was performed to develop an LLPS-related prognostic signature for BCa. The CCK8, wound healing and Transwell assays were performed.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Based on 62 differentially expressed LLPS-related genes (DELRGs), three DELRGs were screened by LASSO analysis including kallikrein-related peptidase 5 (KLK5), monoacylglycerol O-acyltransferase 2 (MOGAT2) and S100 calcium-binding protein A7 (S100A7). Based on three DELRGs, a novel LLPS-related prognostic signature was constructed for individualized prognosis assessment. Kaplan–Meier curve analyses showed that LLPS-related prognostic signature was significantly correlated with overall survival (OS) of BCa. ROC analyses demonstrated the LLPS-related prognostic signature performed well in predicting the prognosis of BCa patients in the training group (the area under the curve (AUC) = 0.733), which was externally verified in the validation cohort 1 (AUC = 0.794) and validation cohort 2 (AUC = 0.766). Further experiments demonstrated that inhibiting KLK5 could affect the proliferation, migration, and invasion of BCa cells.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>In this study, a novel LLPS-related prognostic signature was successfully developed and validated, demonstrating strong performance in predicting the prognosis of BCa patients.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142184502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Translational Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1